This message was sent to ##Email##
|
| December 27, 2017 |
| |  | | |
|
|
|
| |
|
As 2017 comes to a close, ASCT would like to wish its members, partners and other industry professionals a safe and happy holiday season. As we reflect on the past year for the industry, we would like to provide the readers of ASCT Viewpoint a look at the most accessed articles from the year. Our regular publication will resume Wednesday, Jan. 10.
|
| ASCT's response to the USPSTF draft guidelines
|
    |
ASCT
From Oct. 11: ASCT recently worked with the other member organizations of the Cytotechnology Education and Technology Consortium (CETC) to respond to the draft guidelines for cervical cancer screening that were recently released by the United States Preventative Services Task Force (USPSTF). The text of that letter can be seen here. We would like thank those of you who took the time to send in your own individual responses during the public comment period. Our hope is that the USPSTF will take our concerns into consideration as they finalize their recommendations.
Genome Web
From Oct. 11: Lab industry stakeholders are expressing concerns over new draft recommendations for cervical cancer screening, saying they may be difficult to implement. Recently, the U.S. Preventative Services Task Force issued draft recommendations saying women aged 30 to 65 can be screened for cervical cancer either every three years using a Pap smear, or every five years with high risk human papillomavirus testing alone.
READ MORE
University of California Riverside via ScienceDaily
From Aug. 9: When a woman has an abnormal pap smear she usually undergoes a colposcopy. Typically a metal instrument is used to obtain a small sampling of cells inside the cervix — an oftentimes painful procedure for the patient. Now researchers have tested an alternative device called fabric-based endocervical curettage. This less painful device had significantly fewer "inadequate" specimens — meaning, patients didn't need to return for repeat biopsies.
READ MORE
 |
|
Surgilube® has been the preferred sterile lubricant in the medical community since 1932. It is the only sterile carbomer-free lubricant deemed appropriate for use by all leading Pap test manufacturers when a lubricant is necessary. Surgilube has undergone stringent and periodic testing and has met established quality parameters without impacting Pap test results.
|
|
Cancer Network
From July 12: Women who undergo human papillomavirus testing following a test showing abnormal cytology have earlier detection of high-grade cervical intraepithelial neoplasia, compared to those who do not undergo HPV testing, according to a new study. The higher rates of detection come at the expense of increased biopsy and electrosurgical excision rates.
READ MORE
Science Daily
From May 10: Artificial intelligence — commonly known as A.I. — is already exceeding human abilities. Self-driving cars use A.I. to perform some tasks more safely than people. E-commerce companies use A.I. to tailor product ads to customers' tastes quicker and with more precision than any breathing marketing analyst.
READ MORE
Medical Daily
From Jan. 25: Doctors may be able to better tailor cervical cancer treatments to different patients with the discovery of a new subtype of the disease.
Although almost all cervical cancers can be traced back to a longlasting infection of human papillomavirus, a study in the journal Oncotarget found that in some tumors containing DNA of that virus, the HPV was actually inactive — the cancers were triggered by HPV, but the virus did not direct the cancer’s progression.
READ MORE
HealthDay News via U.S. News & World Report
From Sept. 13: Fewer adult women are becoming infected with human papillomavirus, a trend that includes females who have never received the HPV vaccine, a new study reports. It appears that enough women have gotten the HPV vaccine to create "herd immunity" that will provide some protection to females who go unvaccinated, said lead researcher Dr. Abbey Berenson.
READ MORE
CNN
From Feb. 8: The risk of dying from cervical cancer might be much higher than experts previously thought, and women are encouraged to continue recommended cancer screenings.
Black women are dying from cervical cancer at a rate 77 percent higher than previously thought, and white women are dying at a rate 47 percent higher, according to a study published in the journal Cancer.
READ MORE
The Scientist
From Jan. 11: In November, a Japanese team of researchers published a study in Scientific Reports describing the negative outcomes suffered by mice given the vaccine for human papillomavirus. But researchers and doctors have criticized the study and are now calling for its retraction, Science reported.
The paper describes how vaccinated animals exhibited "neurological phenotypes," including limited mobility, and suffered damage to the hypothalamus and other brain regions — effects the authors suggest may shed light on recent reports of the vaccine's adverse effects in humans, similar to the symptoms of chronic fatigue syndrome.
READ MORE
Healio
From Aug. 23: The proportion of oropharyngeal cancers associated with HPV in several cancer centers across Canada rose from nearly half to nearly three-quarters over 12 years, according to researchers. "Across multiple centers in Canada, there was a steady rise in the proportion of oropharyngeal cancers attributable to HPV from 2000 to 2012," study researcher Steven Habbous, MSc, of the Ontario Cancer Institute, and colleagues wrote in the Canadian Medical Association Journal.
READ MORE
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
